Effect of Sensorimotor Training on Upper Extremity in Parkinson's Patients
Trial
N/A
Completed
Feb. 21, 2024
LONG TERM EFFECTS OF SPINAL CORD STIMULATION
Trial
N/A
Unknown
Feb. 21, 2024
tDCS for Dual-task Performance in Patients With PD
Trial
N/A
Completed
Feb. 19, 2024
Optimal Verbal Instruction to Improve Walking for PD
Trial
N/A
Completed
Feb. 19, 2024
Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET)
Trial
Phase 2
Completed
Feb. 19, 2024
A Prospective Study to Evaluate the Correlation Between Oculometric Measurements and Clinical Endpoints in PD Patients
Trial
N/A
Completed
Feb. 15, 2024
The Experience in Neurorehabilitation Setting: a Qualitative Study
Trial
N/A
Unknown
Feb. 15, 2024
Speed Manipulated Adaptive Rehabilitation Therapy Bike for Parkinson's Disease
Trial
N/A
Unknown
Feb. 15, 2024
Effect of Deep Brain Stimulation on Gait of Patients With Parkinson's Disease Depending on Electrode Location in Subthalamic Area
Trial
Phase 4
Completed
Feb. 14, 2024
Effect of Mental Imagery Training on Brain Plasticity and Motor Function in Individuals With Parkinson's Disease
Trial
N/A
Completed
Feb. 14, 2024
Assessment of a Special Modality of Back Muscles Strengthening for Postural Deformations in Parkinsonian Patient
Trial
N/A
Recruiting
Feb. 13, 2024
Sleep, Awake & Move - Part I
Trial
N/A
Completed
Feb. 12, 2024
INfusion VErsus STimulation in Parkinson's Disease
Trial
Phase 4
Completed
Feb. 12, 2024
Transcutaneous Afferent Patterned Stimulation (TAPS) for Reduction of Parkinson's Disease (PD) Related Action Tremor
Trial
N/A
Completed
Feb. 12, 2024
Development and Validation of a Scale Measuring Preoperative Expectations in Parkinson's Disease
Trial
N/A
Completed
Feb. 11, 2024
Domperidone and Risk of Sudden Cardiac Death
Trial
N/A
Completed
Feb. 8, 2024
Microbiome Composition and Function Contributes to Cognitive Impairment and Neuroinflammation in Parkinson's Disease
Trial
N/A
Unknown
Feb. 7, 2024
High-Dose Ambroxol in GBA1-Related Parkinson
Trial
Phase 1
Unknown
Feb. 7, 2024
Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease
Trial
Phase 1
Completed
Feb. 7, 2024